Aileron Therapeutics ALRN

$ 2.79 -2.11%

Quarterly report 2024-Q3
added 11-14-2024

Aileron Therapeutics Financial Statements 2011-2024 | ALRN

Annual Financial Statements Aileron Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	27.3 M	6.67 M	1.9 M	59.8 M	17.5 M	15.9 M	68.8 M	-	-	-	-	-	-
Shares	4.6 M	4.54 M	4.44 M	39.3 M	24.5 M	14.7 M	7.44 M	-	-	-	-	-	-
Historical Prices	5.93	1.47	0.427	1.52	0.585	1.66	8.21	-	-	-	-	-	-
Net Income	-15.7 M	-27.3 M	-26.2 M	-27.3 M	-29.4 M	-31.5 M	-22.6 M	-18.1 M	-12.9 M	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-16.3 M	-27.6 M	-26.6 M	-20.5 M	-30 M	-31.9 M	-23 M	-18.2 M	-12.9 M	-	-	-	-
Interest Expense	544 K	318 K	441 K	-661 K	587 K	-	-	-	-	-	-	-	-
EBITDA	-16.2 M	-27.5 M	-26.5 M	-20.3 M	-29.8 M	-31.7 M	-22.9 M	-17.9 M	-12.6 M	-	-	-	-
Operating Expenses	16.3 M	27.6 M	26.6 M	20.5 M	30 M	31.9 M	23 M	-	-	-	-	-	-
General and Administrative Expenses	11.4 M	9.68 M	9.6 M	9.33 M	12.3 M	13.5 M	8.77 M	-	5.06 M	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Aileron Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	21.7 M	19.9 M	8.3 M	4.89 M	4.54 M	4.54 M	4.54 M	4.54 M	4.54 M	4.54 M	4.53 M	90.6 M	90.5 M	90.5 M	83.4 M	41 M	39.3 M	31.2 M	27.8 M	27.8 M	27.8 M	27.5 M	14.8 M	14.7 M	14.7 M	14.7 M	14.7 M	14.7 M	13.9 M	450 K	433 K	432 K	431 K	429 K	426 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-5.85 M	-8.94 M	-7.11 M	-	-1.83 M	-1.79 M	-4.78 M	-	-6.37 M	-7.99 M	-8.42 M	-	-6.7 M	-5.69 M	-6.98 M	-4.93 M	-5.02 M	-4.39 M	-6.75 M	-7.24 M	-7.75 M	-7.17 M	-7.21 M	-7.03 M	-7.43 M	-9.49 M	-7.59 M	-6.86 M	-6.26 M	-4.92 M	-4.56 M	-4.44 M	-4.22 M	-5.53 M	-3.92 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-6.07 M	-9.04 M	-7.2 M	-	-1.98 M	-1.99 M	-5.01 M	-	-6.48 M	-8.04 M	-8.42 M	-	-6.79 M	-6.01 M	-6.99 M	-4.19 M	-5.03 M	-4.4 M	-6.88 M	-7.35 M	-7.92 M	-7.38 M	-7.31 M	-6.98 M	-7.5 M	-9.66 M	-7.76 M	-7.04 M	-6.43 M	-4.95 M	-4.59 M	-4.45 M	-4.23 M	-5.55 M	-3.94 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	224 K	97 K	92 K	-	156 K	205 K	232 K	-	4 K	-	-22 K	-	66 K	304 K	-	-738 K	5 K	10 K	62 K	112 K	166 K	208 K	101 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-7.15 M	-	-	-	-4.97 M	-	-6.36 M	-7.96 M	-8.38 M	-	-6.71 M	-5.97 M	-6.99 M	-4.19 M	-4.88 M	-4.26 M	-6.81 M	-7.35 M	-7.84 M	-7.32 M	-7.28 M	-6.98 M	-7.33 M	-9.58 M	-7.72 M	-7.04 M	-6.34 M	-4.91 M	-4.57 M	-4.45 M	-4.04 M	-5.42 M	-3.94 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	6.07 M	9.04 M	7.2 M	-	1.98 M	1.99 M	5.01 M	-	6.48 M	8.04 M	8.42 M	-	6.79 M	6.01 M	6.99 M	4.19 M	5.03 M	4.4 M	6.88 M	7.35 M	7.92 M	7.38 M	7.31 M	6.98 M	7.5 M	9.66 M	7.76 M	7.04 M	6.43 M	4.95 M	4.59 M	4.45 M	4.23 M	5.55 M	3.94 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	2.35 M	5.3 M	3.74 M	-	1.96 M	1.89 M	2.18 M	-	2.24 M	2.61 M	2.53 M	-	2.51 M	2.16 M	2.67 M	2.27 M	2.34 M	1.91 M	2.81 M	2.64 M	3.44 M	3.08 M	3.14 M	3.02 M	3.18 M	4.34 M	2.92 M	2.73 M	2.6 M	1.79 M	1.65 M	1.36 M	1.63 M	3.46 M	1.45 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency